3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, B-Cell
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Recurrence
1
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
1
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Klatskin Tumor
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Bevacizumab
69
Sorafenib
66
lenvatinib
59
durvalumab
38
sintilimab
33
Nivolumab
32
tislelizumab
28
atezolizumab
28
pembrolizumab
27
Oxaliplatin
26
tremelimumab
23
apatinib
22
Fluorouracil
22
Radiosurgery
20
regorafenib
19
camrelizumab
18
Doxorubicin
18
cabozantinib
16
Leucovorin
16
Capecitabine
16
Radiotherapy
14
Folfox protocol
14
donafenib
13
Gemcitabine
13
Cisplatin
12
toripalimab
11
Erlotinib Hydrochloride
10
spartalizumab
8
anlotinib
8
Neoadjuvant Therapy
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Hepatocellular
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT05517239
2022-08-26
PEACH
Yonsei University
Phase 2
Completed
32 enrolled